Menarini and Ryvu Announce First Dapolsertib Phase II Data

The companies announced initial results from the Phase II JASPIS-01 study of dapolsertib monotherapy in heavily pretreated relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, presented at the 2026 ASH Annual Meeting.